Literature DB >> 11144897

Cellular and molecular pathology of prostate cancer precursors.

C S Foster1, D G Bostwick, H Bonkhoff, J E Damber, T van der Kwast, R Montironi, W A Sakr.   

Abstract

Prostate cancer is usually heterogeneous and multifocal, with diverse clinical and morphologic manifestations. Current understanding of the molecular basis for this heterogeneity is limited, particularly for prostatic intraepithelial neoplasia (PIN), the only putative precursor which can be identified according to morphologic criteria. However, it is likely that prostatic adenocarcinoma might arise from precursor lesions other than PIN, although these cannot be recognized with certainty at the present time. In this review, we summarize the current state of knowledge regarding the cell-biological and genetic bases for linking PIN and prostatic adenocarcinoma. It is conceivable that a stem cell of basal phenotype, or an amplifying cell, is the target of prostatic carcinogenesis. Prominent genetic heterogeneity is characteristic of both PIN and carcinoma; and multiple foci of PIN arise independently within the same prostate. This observation suggests that a field effect probably underlies prostatic neoplasia. Multiple foci of cancer also often arise independently, lending additional support to this hypothesis. The strong genetic similarities between PIN and cancer strongly suggest that evolution and clonal expansion of PIN, or other precursor lesions, may account for the multifocal etiology of carcinoma. Uncertainties with respect to identification of those precursor lesions which are most likely to progress to invasive and metastatic prostate cancer reinforce the requirement for objective immunohistochemical or molecular biological markers of the aggressive phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11144897     DOI: 10.1080/003655900750169284

Source DB:  PubMed          Journal:  Scand J Urol Nephrol Suppl        ISSN: 0300-8886


  11 in total

1.  The identification of chromosomal translocation, t(4;6)(q22;q15), in prostate cancer.

Authors:  L Shan; L Ambroisine; J Clark; R J Yáñez-Muñoz; G Fisher; S C Kudahetti; J Yang; S Kia; X Mao; A Fletcher; P Flohr; S Edwards; G Attard; J De-Bono; B D Young; C S Foster; V Reuter; H Moller; T D Oliver; D M Berney; P Scardino; J Cuzick; C S Cooper; Y-J Lu
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-02-23       Impact factor: 5.554

2.  TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions.

Authors:  Nuno Cerveira; Franclim R Ribeiro; Ana Peixoto; Vera Costa; Rui Henrique; Carmen Jerónimo; Manuel R Teixeira
Journal:  Neoplasia       Date:  2006-10       Impact factor: 5.715

Review 3.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

4.  [Implications of estrogens and their receptors for the development and progression of prostate cancer].

Authors:  H Bonkhoff; T Fixemer
Journal:  Pathologe       Date:  2005-11       Impact factor: 1.011

Review 5.  My approach to intraductal lesions of the prostate gland.

Authors:  M Pickup; T H Van der Kwast
Journal:  J Clin Pathol       Date:  2007-01-19       Impact factor: 3.411

6.  Dietary Pterostilbene for MTA1-Targeted Interception in High-Risk Premalignant Prostate Cancer.

Authors:  Rutu Hemani; Ishani Patel; Ninad Inamdar; Gisella Campanelli; Virginia Donovan; Avinash Kumar; Anait S Levenson
Journal:  Cancer Prev Res (Phila)       Date:  2021-10-21

Review 7.  [New insights into the role of estogens and their receptors in prostate cancer].

Authors:  H Bonkhoff; H Motherby; T Fixemer
Journal:  Urologe A       Date:  2003-12       Impact factor: 0.639

8.  Hsp-27 expression at diagnosis predicts poor clinical outcome in prostate cancer independent of ETS-gene rearrangement.

Authors:  C S Foster; A R Dodson; L Ambroisine; G Fisher; H Møller; J Clark; G Attard; J De-Bono; P Scardino; V E Reuter; C S Cooper; D M Berney; J Cuzick
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

9.  Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer.

Authors:  G Attard; J Clark; L Ambroisine; G Fisher; G Kovacs; P Flohr; D Berney; C S Foster; A Fletcher; W L Gerald; H Moller; V Reuter; J S De Bono; P Scardino; J Cuzick; C S Cooper
Journal:  Oncogene       Date:  2007-07-16       Impact factor: 9.867

10.  cGMP-dependent protein kinase Iβ interacts with p44/WDR77 to regulate androgen receptor-driven gene expression.

Authors:  Liran Zhou; Keiko Hosohata; Shen Gao; Zhongping Gu; Zhengxin Wang
Journal:  PLoS One       Date:  2013-06-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.